Primary XXXX --a retrospective study. Experience at the Northern Israel Oncology Center (1979-2000).

@entity1 @entity632 @entity706 @entity4349 @entity5 @entity3478 @entity2
OBJECTIVE: This retrospective study describes our experience with the diagnosis, treatment, results and long-term follow-up of @entity706 ( @entity706 ). @entity1 AND METHODS: Nineteen @entity1 diagnosed with @entity706 were reviewed. Seven @entity1 presented with stage I(E) disease, four with stage II(E) (regional lymphadenopathy), and eight with @entity5 (disseminated bone involvement). Only one stage IV @entity1 exhibited 'B' symptoms. The majority (72%) demonstrated diffuse, large cell, B-type @entity706 . All @entity1 were treated with @entity632 -based chemotherapy and consolidation radiotherapy to the primary site (8 @entity1 : early @entity706 ) or the most bulky area (3 @entity1 : stage IV @entity706 ). RESULTS: Ten stage I(E)/II(E) @entity1 are alive with no evidence of disease (NED) and only one died due to metastatic @entity2 while with NED from his @entity706 . Eight stage IV @entity1 are alive with NED. Median follow-up for all living @entity1 : 77 months. Side effects were mild and did not necessitate delay in treatment. CONCLUSIONS: Our departmental policy of treating @entity706 @entity1 with an @entity4349 -based regimen and involved field radiotherapy proved to be successful in achieving excellent long-term, disease-free survival. Phase III randomized, controlled, clinical trials will determine the true role of consolidation radiotherapy in @entity706 , when considering severe late side effects, including radiation-induced @entity3478 .
